青藤碱治疗高尿酸血症的研究进展
Research Progress in the Treatment of Hyperuricemia with Sinomenine
摘要: 随着饮食与生活方式改变,我国高尿酸血症患病率持续上升且呈年轻化,已成为重要代谢性疾病。临床常用降尿酸药物存在过敏、肝肾损伤、心血管风险等局限,多靶点、低毒的中药单体成为研发热点。青藤碱是青风藤的主要活性成分,兼具抗炎、免疫调节、利尿、肾保护与代谢调控等作用。近年研究表明,青藤碱可通过抑制黄嘌呤氧化酶活性减少尿酸生成、调控肾小管尿酸转运体促进尿酸排泄、抑制NLRP3 炎症小体与氧化应激减轻靶器官损伤、改善糖脂代谢紊乱等多通路、多靶点发挥降尿酸效应,动物实验与初步临床观察均证实其疗效确切、安全性较好。但目前仍存在高质量临床研究不足、作用机制未完全阐明、生物利用度偏低等问题。本文系统综述高尿酸血症发病机制、临床治疗困境、青藤碱药理特性、降尿酸机制及实验与临床研究进展,并展望未来研究方向,为青藤碱用于高尿酸血症的基础研究与临床转化提供参考。
Abstract: With changes in diet and lifestyle, the prevalence of hyperuricemia in China continues to rise and presents a younger trend, making it a major metabolic disease. Commonly used urate-lowering drugs have limitations such as allergy, liver and kidney injury, and cardiovascular risks. Therefore, multi-target and low-toxicity traditional Chinese medicine monomers have become a research hotspot. Sinomenine is the main active component of sinomenium acutum, possessing anti-inflammatory, immunoregulatory, diuretic, renal protective and metabolic regulatory effects. Recent studies have shown that sinomenine exerts urate-lowering effects through multiple pathways and targets, including inhibiting xanthine oxidase activity to reduce uric acid production, regulating renal tubular urate transporters to promote uric acid excretion, suppressing NLRP3 inflammasome and oxidative stress to alleviate target organ damage, and improving glycolipid metabolic disorders. Both animal experiments and preliminary clinical observations have confirmed its favorable efficacy and safety. However, there are still problems such as insufficient high-quality clinical studies, incompletely clarified mechanisms, and low bioavailability. This paper systematically reviews the pathogenesis of hyperuricemia, clinical treatment dilemmas, pharmacological properties of sinomenine, urate-lowering mechanisms, as well as advances in experimental and clinical research, and prospects future directions, so as to provide references for basic research and clinical translation of sinomenine in hyperuricemia.
文章引用:侯梦梦, 邓明欣, 顾炳坤, 朱冰冰, 尚曙玉, 张翠利. 青藤碱治疗高尿酸血症的研究进展[J]. 药物化学, 2026, 14(2): 205-212. https://doi.org/10.12677/hjmce.2026.142020

参考文献

[1] Chen, C.Y., Lane, H.Y. and Lin, C.H. (2016) Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences. Clinical Psychopharmacology and Neuroscience, 14, 238-249. [Google Scholar] [CrossRef] [PubMed]
[2] Zhang, W., Wang, J., Wu, Y., Xia, Y., Sun, Z. and Wu, Y. (2025) Development and Validation of the Nutrition Literacy Scale for Chinese Gout Patients. PLOS ONE, 20, e0318259. [Google Scholar] [CrossRef] [PubMed]
[3] Zhang, T., Liu, W. and Gao, S. (2024) Exercise and Hyperuricemia: An Opinion Article. Annals of Medicine, 56, Article ID: 2396075. [Google Scholar] [CrossRef] [PubMed]
[4] Jiang, Z.M., Zeng, S.L., Huang, T.Q., Lin, Y., Wang, F., Gao, X., et al. (2023) Sinomenine Ameliorates Rheumatoid Arthritis by Modulating Tryptophan Metabolism and Activating Aryl Hydrocarbon Receptor via Gut Microbiota Regulation. Science Bulletin, 68, 1540-1555. [Google Scholar] [CrossRef] [PubMed]
[5] Jiang, W., Fan, W., Gao, T., Li, T., Yin, Z., Guo, H., et al. (2020) Analgesic Mechanism of Sinomenine against Chronic Pain. Pain Research and Management, 2020, Article ID: 1876862. [Google Scholar] [CrossRef] [PubMed]
[6] Ben Salem, C., Slim, R., Fathallah, N. and Hmouda, H. (2017) Drug-Induced Hyperuricaemia and Gout. Rheumatology, 56, 679-688. [Google Scholar] [CrossRef] [PubMed]
[7] Borghi, C., Agabiti-Rosei, E., Johnson, R.J., Kielstein, J.T., Lurbe, E., Mancia, G., et al. (2020) Hyperuricaemia and Gout in Cardiovascular, Metabolic and Kidney Disease. European Journal of Internal Medicine, 80, 1-11. [Google Scholar] [CrossRef] [PubMed]
[8] Yang, H., Chen, Q., Huang, A., Yu, X., Chen, G., Hu, X., et al. (2021) Impact of Hyperuricemia on Long-Term Clinical Outcomes of Renal Transplant Recipients: A Systematic Review and Meta-Analysis. Journal of Pharmacy & Pharmaceutical Sciences, 24, 292-307. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, Q., Li, H., Xing, D. and Lin, J. (2022) Global Research Trends in Hyperuricemia: A Bibliometric and Visualized Study. Modern Rheumatology, 32, 619-625. [Google Scholar] [CrossRef] [PubMed]
[10] Chi, X., Cen, Y., Yang, B., Zhang, H., Pu, Z., Feng, J., et al. (2024) Effects of Dietary Factors on Hyperuricaemia and Gout: A Systematic Review and Meta-Analysis of Observational Studies. International Journal of Food Sciences and Nutrition, 75, 753-773. [Google Scholar] [CrossRef] [PubMed]
[11] Ren, Q., Tao, S., Guo, F., Wang, B., Yang, L., Ma, L., et al. (2021) Natural Flavonol Fisetin Attenuated Hyperuricemic Nephropathy via Inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 Signaling. Phytomedicine, 87, Article ID: 153552. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, Y., Wang, S., Dai, X., Liu, T., Liu, Y., Shi, H., et al. (2023) Simiao San Alleviates Hyperuricemia and Kidney Inflammation by Inhibiting NLRP3 Inflammasome and JAK2/STAT3 Signaling in Hyperuricemia Mice. Journal of Ethnopharmacology, 312, Article ID: 116530. [Google Scholar] [CrossRef] [PubMed]
[13] Becker, M.A., Schumacher, H.R., Wortmann, R.L., MacDonald, P.A., Eustace, D., Palo, W.A., et al. (2005) Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. New England Journal of Medicine, 353, 2450-2461. [Google Scholar] [CrossRef] [PubMed]
[14] Hou, Z., Ma, A., Mao, J., Song, D. and Zhao, X. (2023) Overview of the Pharmacokinetics and Pharmacodynamics of URAT1 Inhibitors for the Treatment of Hyperuricemia and Gout. Expert Opinion on Drug Metabolism & Toxicology, 19, 895-909. [Google Scholar] [CrossRef] [PubMed]
[15] Wu, F., Chen, L. and Du, Y. (2024) Comparison of the Efficacy and Safety of Benzbromarone and Febuxostat in Gout and Hyperuricemia: A Systematic Review and Meta-Analysis. Clinical Rheumatology, 43, 1745-1754. [Google Scholar] [CrossRef] [PubMed]
[16] 刘晶晶, 刘孙丽, 朱凯驿, 等. 青藤碱在心血管疾病中的研究进展[J]. 中西医结合心脑血管病杂志, 2026, 24(5): 702-705.
[17] 黄海, 张秉祺, 曾凡学, 等. 青藤碱通过PI3K/AKT/mTOR自噬信号通路改善糖尿病肾病大鼠肾损害的机制研究[J]. 中药材, 2026(1): 183-188.
[18] 但武龙, 杨菁, 陈智勇, 等. 白及多糖和甘草酸共稳定的青藤碱纳米乳的制备及其体外抗炎评价[J]. 中草药, 2026, 57(1): 95-108.
[19] 徐丽, 胡泽玉, 胡明月, 等. 青藤碱通过调控XCL抑制Jurkat细胞增殖与活化的机制研究[J]. 湖南中医药大学学报, 2025, 45(12): 2288-2295.
[20] 庞亮, 刘峰, 赵翠翠. 基于网络药理学、分子动力学模拟以及转录基因组学探讨青藤碱治疗膀胱癌的机制研究[J]. 南开大学学报(自然科学版), 2025, 58(6): 74-83.
[21] 张成强, 张敏, 李东梅, 等. 青藤碱通过Toll样受体4和髓系分化因子88依赖途径抑制类风湿关节炎Th1/Th2细胞比值增加的研究[J]. 中国药物与临床, 2025, 25(22): 1454-1462.
[22] Zhao, W., Chen, J., Zuo, H., Jiao, Y., Wang, F., Du, W., et al. (2025) Development of P(NVCL)-Based Transdermal Patches for Sinomenine Hydrochloride Delivery in Gouty Arthritis. Colloids and Surfaces B: Biointerfaces, 256, Article ID: 115055. [Google Scholar] [CrossRef] [PubMed]
[23] 张珊. 青藤碱通过调控NETs形成和巨噬细胞M1极化减轻痛风炎症的机制研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2025.
[24] 段新宇, 霍志鹏, 冯心池, 等. 青藤碱治疗痛风性关节炎的药理研究进展[J]. 天津药学, 2024, 36(1): 73-78.
[25] 陈勇, 邓家刚, 王勤, 等. 抗痛风颗粒中青风藤TLC鉴别与青藤碱的含量测定[J]. 中国实验方剂学杂志, 2007(6): 11-13.
[26] 李勇, 朱怡洁, 何伟. HPLC法测定痛风胶囊中青藤碱和大黄酸的含量[J]. 广东药学院学报, 2012, 28(2): 163-166.
[27] 马国海, 胡继民, 吴杰. 盐酸青藤碱关节注射治疗急性踝关节痛风性关节炎之我见[J]. 卫生职业教育, 2011, 29(24): 147.
[28] 刘瑶. 青藤碱定点介入治疗痛风性关节炎的临床效果观察[J]. 中外医学研究, 2021, 19(18): 55-57.
[29] 侯新聚, 马红梅, 朱满华. 运用红外热像评价青藤碱定点介入治疗痛风性关节炎的临床疗效观察[J]. 临床医药实践, 2020, 29(8): 563-566.
[30] 张芳红, 王永昌, 杨义军, 等. 高效液相色谱法测定痛风安胶囊中青藤碱的含量[C]//药物分析杂志编辑部. 色谱分析在药物分析中的应用专题学术研讨会论文集. 兰州: 甘肃省医学科学研究院, 2004: 30.
[31] 尹智功, 肖敬, 谢议凤, 等. 青藤碱对老年急性痛风性膝关节炎的临床与实验研究[Z]. 柳州市中医医院. 2020.
[32] 李元耿, 孙刚, 丁羽, 等. 青藤碱注射液关节内注射治疗痛风性关节炎的实验研究[J]. 中国药物经济学, 2018, 13(11): 72-74.
[33] 肖敬, 冯双燕, 李昆英, 等. 青藤碱对痛风性关节炎大鼠模型滑膜组织白细胞介素-6影响实验研究[J]. 辽宁中医药大学学报, 2018, 20(12): 44-47.
[34] 李振彬, 李达, 马旭, 等. 白芍总苷联合青藤碱对尿酸钠诱导巨噬细胞MyD88、NF-κB表达的影响[C]//第十二届全国免疫学学术大会论文集. 2017: 514-514.
[35] 萆薢青藤饮治疗急性痛风性关节炎的临床与实验研究[Z]. 大庆油田总医院. 2009.
[36] 尹智功, 肖敬, 蒋耀平, 等. 青藤碱对痛风性关节炎模型大鼠TNF-α、IL-1β及COX-2的影响[J]. 广西中医药, 2015, 38(4): 71-74.
[37] 肖敬, 尹智功, 刘江, 等. 盐酸青藤碱注射液关节腔冲洗及注射治疗急性痛风性膝关节炎32例[J]. 中国中医药现代远程教育, 2013, 11(6): 9-10.
[38] 粟戟, 李蕴麟. 青藤碱关节腔内注射治疗急性痛风性膝关节炎的临床观察[J]. 甘肃医药, 2012, 31(5): 338-341.
[39] Jia, E., Hu, S., Geng, H., Zhu, H., Xie, J., Xiao, Y., et al. (2022) Zhengqing Fengtongning Sustained-Release Tablets Prevents Gout Flares in the Process of ULT: A Randomized, Positive Control, Double-Blind, Double-Simulation, Multicenter Trial. Medicine, 101, e29199. [Google Scholar] [CrossRef] [PubMed]
[40] 贾二涛, 何思慧, 黄俊杰, 等. 青藤碱治疗痛风性关节炎研究现状[J]. 贵州中医药大学学报, 2022, 44(3): 66-70.
[41] 郑爽, 何忠梅, 宗颖, 等. 盐酸青藤碱在急性痛风大鼠体内的排泄动力学研究[J]. 中成药, 2021, 43(12): 3275-3279.
[42] 肖梦琪, 沈小兰, 郭响, 等. PIK3CG作为青藤碱治疗类风湿关节炎关键靶点的生物信息学筛选与实验验证[J]. 中国免疫学杂志, 2026, 42(3): 606-615.
[43] Zhang, S., Tan, H., Zhang, Z., Wang, Z., Zhang, C., Zhang, J., et al. (2025) Sinomenine Alleviates Gouty Inflammation by Inhibiting Macrophage M1 Polarization and Neutrophil Extracellular Trap Formation. Naunyn-Schmiedebergs Archives of Pharmacology, 398, 15791-15805. [Google Scholar] [CrossRef] [PubMed]
[44] 李达. 青藤碱联合白芍总苷对尿酸钠晶体诱导RAW264.7巨噬细胞MyD88、NF-κB、ASC、Caspase-1表达的影响[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2017.